巨子 ICON - 財經股票資訊及專家分析
搜尋 股票

Galmed Pharmaceuticals Ltd

GLMD
最少15分鐘延遲,股票資訊由第三方資訊供應商提供
・Galmed Pharmaceuticals Ltd - 延遲價格・最後更新於 26/01 8:25
最高位
1.560
最低位
1.530
開市價
--
前收市價
1.500
成交量(千)
0.41
成交額(百萬)
0.00
買入
--
賣出
--
每手股數
--
市值(百萬)
38.38
市盈率
--
息率
--
差價
--
52週高低
6.250 - 1.330
所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

企業資料

公司名稱
Galmed Pharmaceuticals Ltd
證券代碼
GLMD.US
所屬板塊
Biotechnology
公司業務
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
發行量
25083914
公司總部
16 Tiomkin Street
公司網址
https://www.galmedpharma.com
公司電郵
info@galmedpharma.com
公司電話
+972 36938448
暫無內容

關於

Galmed Pharmaceuticals Ltd(GLMD.US)所屬的行業板塊為Biotechnology。
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
詳細公司背景可參考: https://www.galmedpharma.com